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Mohamdod Saber Alzer: Muscle Cross-Sectional Area is Improved and Physical Function is 
Maintained in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen 
Deprivation Therapy 
(Under the direction of [Erik Hanson]) 
Exercise has been shown to be beneficial in alleviating detriments from androgen 
deprivation therapy (ADT). However, little work has been done examining the effects on less 
resource-intensive exercise in progressive forms of prostate cancer (PCa). The purpose of this 
study was to evaluate the effects of a home-based exercise program on muscle cross sectional 
area and physical function in men with metastatic castration-resistant prostate cancer (mCRPC) 
undergoing ADT. 
 For mCRPC patients completing the intervention (n=14), VL CSA increased by 12.6% 
(pre: 8.7cm2 ± 3.3, post: 9.8 ± 3.9, p=0.012, d= 0.32) with no change in MQ. Those who met the 
adherence threshold experienced greater hypertrophy (n=9; pre: 9.27cm2 ± 3.1, post: 11.77cm2 ± 
4.0; d= 0.7). PF was maintained after exercise training. VL CSA was lower in mCRPC (9.12cm2 
+ 3.15) relative to CON (36.55cm2 ± 7.04, p<0.001, d=4.95). Results are encouraging, but more 
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Prostate cancer (PCa) is the most commonly diagnosed and second most fatal cancer 
amongst men with approximately 165,000 diagnoses and 27,000 deaths occurring annually1. 
Although treatment advancements have been made, the number of incidences are still high 
relative to other forms of cancer1. The 5-year survival rate for localized PCa is >95%; however, 
metastatic prostate cancer (mPCa) has survival rates of ~30%, which varies based upon the 
location of metastasis and medications prescribed to those diagnosed1–4.  
PCa is a hormone-sensitive disease, with development and progression reliant on 
interactions between circulating androgen and androgen-cell receptors5. Those with localized 
PCa may undergo prostatectomy to remove the tumor, but are often prescribed androgen 
deprivation therapy (ADT) in the form of a gonadotrophin-releasing-hormone (GnRH) agonist to 
reduce the possibility of tumor proliferation after surgery6. ADT has previously been shown to 
effectively treat PCa by slowing the rate of disease progression, but PCa will likely (typically 2-3 
years) progress into a hormone-insensitive phase7–9 where the tumor independently upregulates 
androgen signaling8,9. Secondary forms of ADT are now often required (in conjunction with 
primary ADT via GnRH agonists) to induce a “super-castration” effect3,5,10. Men who reach this 
progression of the disease are clinically diagnosed with metastatic, castration-resistant prostate 
cancer (mCRPC)3.  
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Although the additional ADT dosage increases survival by 4-5 months11,12, side effects 
are further exacerbated relative to baseline ADT dosages, significantly decreasing muscle mass 
and physical function, increasing fatigue, and lowering overall QoL13,14. Individuals with 
mCRPC commonly become more sedentary, with disuse-atrophy further exacerbating symptoms 
of ADT15,16. Exercise training is one approach that helps counteract some of the negative side 
effects associated with ADT in less progressive forms of prostate cancer. However, far less is 
known regarding how exercise training affects physiological parameters in those diagnosed with 
mCRPC. This represents a key knowledge gap, as men with mCRPC face additional challenges 
due to additional forms of ADT.  
ADT 
 
ADT has been shown to be an effective anti-cancer treatment for PCa4,17, comes in 
several different forms (e.g. Primary ADT such as GnRH agonists, Secondary ADT such as 
androgen receptor antagonists, and androgen synthesis inhibitors; see ADT section in Chapter 2), 
and is associated with numerous adverse side effects16,18–20. Those who are considered mCRPC 
face additional challenges due to the introduction of “super ADT” drugs, which further amplify 
androgen depletion13,21. Although the spread of cancer may be controlled, patients commonly 
experience muscular atrophy, as well as decreases to lean mass due to the effects of low 
testosterone.  Following the initiation of super-castration (ADT + abiraterone),  4.3% of total 
body muscle mass was lost during the first 12 months, illustrating the severity of side effects10. 
Additionally, individuals undergoing super-castration levels of ADT have previously been 
shown to experience increases to sarcopenia, which in turn affects physical function12,13,22. 
Overall, this affects the ability to perform activities of daily living (ADLs)23, suggesting the need 
to critically examine muscle variables as clinically relevant outcomes for this population. 
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Muscle Quality and Cross-sectional Area 
 
 Muscle size and quality are of particular interest in elderly populations and men with PCa 
on ADT due to their clinical significance24,25. Cross-sectional area (CSA) describes muscle size26 
and is a valuable physiological measurement due to its positive correlation with strength and 
function27,28. However, muscle atrophy (decreased CSA) occurs with aging and is a likely 
contributor to loss of force and the inability to perform ADLs effectively29,30. These decreases 
are of particular concern to those with mCRPC undergoing ADT, as the average age of an 
individual diagnosed with mCRPC is 74 years31, suggesting that this population is already at risk 
for age-related declines in muscle mass which are accelerated by the use of ADT18,32. 
Additionally, aging affects other myogenic variables such as muscle quality (MQ)28, which is a 
muscle’s capacity to generate force per unit size33. Declines in strength are not strictly due to 
sarcopenia, but may be attributed to how aging affects MQ34. Changes to MQ may include a 
decrease to the number of contractile proteins or an increase in the amount of intramuscular 
triglycerides present24,34, with the latter potentially maintaining the muscle size but not force. To 
our knowledge, only one study has examined MQ in men with PCa on ADT, in which 
participants experienced an 18.9% decrease after 20 weeks of treatment35. The combination of 
ADT and sedentary lifestyle behaviors suggests that those with mCRPC are prone to severe 
detriments to MQ and CSA, which are related to muscular strength and function. Ultimately, this 
affects overall QoL30,36, emphasizing the need for therapeutic remedies to counteract these 
deleterious events35. Exercise interventions in particular have the potential to help to reverse the 
side effects of ADT.  
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Exercise in PCa 
Exercise training, which may include combined RT and AE, is a powerful, 
complementary therapy for reducing ADT-related side effects37–39, but the majority of reported 
benefits from exercise interventions regarding PCa patients on ADT do not specifically include 
those diagnosed with mCRPC37,39–41. Resistance training (RT) particularly has elicited 
improvements with minimal occurrences of adverse events in both localized and metastatic 
disease. While testosterone ablation is not conducive to maintaining muscle mass10,25,40 our 
group has demonstrated that individuals with localized PCa undergoing ADT were able to 
experience increases in muscle protein synthesis42 and muscle hypertrophy39 and were similar to 
healthy men that also led to improvements to physical function, muscle endurance, and QoL39. 
RT trials involving metastatic PCa participants have been able to illustrate benefits as well, with 
improvements in physical function, activity levels, lean mass, and lower body strength37,38. 
Additionally, aerobic exercise has also shown to be beneficial by providing an unfavorable 
microenvironment for tumor development43, and helps to improve cardiorespiratory fitness and 
self-reported physical function44. Overall, there is emerging evidence to suggest that exercise 
training can provide benefits for men with PCa on ADT. However, little is known regarding how 
exercise training may affect men with mCRPC, a group that is likely to have greater ADT-related 
side effects and disease burden. 
To our knowledge, there are two preliminary exercise trials in men with mCRPC. In an 
initial report, men randomized to combined exercise training or usual care with men attempting 
98% of the workouts and completing 78% as prescribed experienced no safety issues (Kenfield 
& Chan, unpublished data). Another single-arm home-based trial is currently underway but has 
yet to report study outcomes46. These ongoing trials, as well as the current study, used home-
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based exercise training. While supervised trials provide the benefits of increased safety, 
motivation, and control, they are also resource intensive and require participants to live close to 
training facilitates (or be willing to travel). Home-based training reduces or removes many of 
these barriers, including access to equipment, travel, socioeconomic status, and functional 
deficits from maximal androgen blockade47. Recent studies have investigated the feasibility of 
home-based exercise trials during ADT for localized PCa48,49. One trial in particular indicated 
that home-based exercise training in men with localized PCa undergoing ADT demonstrated 
similar benefits to fitness and QoL relative to more resource-intensive methods50. Considering 
these outcomes and the challenges faced by individuals diagnosed with mCRPC, remote training 
programs may prove to be a more viable yet physiologically stimulating option. However, little 
is known regarding changes to specific muscle variables after home-based exercise trials and 
how this may affect physical function, especially in mCRPC. Therefore, the aim of this study 
was to analyze muscle CSA and MQ in mCRPC in order to provide researchers with meaningful 
information regarding how home-based exercise affects muscle physiology in this population. 
Additionally, CSA will be compared to a control population, in order to understand the 




1. How does muscle CSA in mCRPC on ADT compare with control populations?  
2. Does a 12-week, home-based exercise intervention produce changes in muscle CSA 
and quality in men with mCRPC on ADT?  
3. Do changes in muscle CSA and quality after a home-based exercise intervention 
correlate with changes in physical function? 




1. Adherence may confound the relationship between muscle cross-sectional area, muscle 
quality, and functionality If there is heterogeneity in improvements, we may need to 




1. A 12-week, home-based exercise intervention will increase vastus lateralis CSA and MQ  
2. Changes in CSA and MQ will positively correlate with physical function 
3. Muscle CSA will be significantly smaller in mCRPC compared to control. 
Limitations 
 
1. Adherence to the exercise program, the resistance training in particular, was self-report. 
The aerobic (walking) portions were verified using wearable activity monitors. 
2.  This was a single-arm study. The primary purpose of this study was to examine 
feasibility, and it was unclear if the intervention was even possible.  
3. All tests were completed in a single testing day. 




1. All subjects were asked to complete all tests in the same day and in the same order, to 
minimize burden and reduce variance.  
2. Adherence will be confirmed through Garmin VivoSmart HR smart-watch technology 
and weekly calls to subjects.  
 




  The analysis of muscle CSA and quality after a home-based exercise protocol allowed 
researchers to better understand how these variables contribute to physical function in this 
population. If the results are found to be significant, and if subjects adhere above our threshold of 
70% to the exercise protocol, health-care practitioners may suggest home-based exercise to 
mCRPC patients on ADT in order to provide a convenient solution to alleviate the negative side 
effects of severe testosterone depletion. Ultimately, the results will provide details of the 
mechanism regarding muscle physiology in this population and will provide guidance for future 
research
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 Cancer accounts for a large proportion of death in today’s world, making research in this 
field of particular interest. Cancer survival rates have exponentially improved over the past 
decade due to advances in early detection and enhanced treatment options51. This indicates that 
diagnosed individuals are living longer with cancer1. These benefits, however, are accompanied 
with consequences. Cancer medications greatly increase patient perceived fatigue, sedentary 
behavior, and ultimately the likelihood of metabolic syndromes and cardiovascular disease19,52,53.  
Although cancer patients are living longer, QoL is severely impacted during this time 
period7,10,54,55 . The number of cancer diagnoses are projected to grow by approximately 20% 
within the next decade as the current population ages,56 suggesting that more people are 
experiencing longer, but more difficult lives. Cancer is clearly a pertinent issue in society, and 
guidelines are needed to help individuals live longer lives that are healthy and meaningful.  
Prostate cancer 
 
 Approximately 1 in 9 men will be diagnosed with prostate cancer at some point in life, 
making it one of the most common cancers in the world; however, only 1 in 41 men will die of 
this disease1. Death rates for PCa have significantly declined over the past forty years due to the 
multiple treatment options that are available for PCa patients, including chemotherapy57, 
radiation therapy58, prostatectomy 2, and ADT53,59. However, many of the medications prescribed 
to PCa patients often lead to high levels of fatigue, due to the deleterious effects they have on the 
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body. Ultimately, this increases sedentary behavior, and leads to higher instances of 
cardiovascular disease, making overall health a critical issue when prescribed cancer 
medications15,16.  
As previously stated, localized PCa has a 5-year survival rate of almost 100%, due to the 
effectiveness of prostatectomy2; however, survival rates drop significantly to 30%60 for those 
with mPCa as the disease has spread to bone structures1. Patients may be prescribed medications 
such as ADT that help to control development of the cancer but leave individuals with harsh side 
effects. In many cases, men are able to live longer, but at an extreme functional 
disadvantage7,18,54.  
ADT 
ADT is an effective treatment solution for men with advanced prostate cancer. As 
prostate cancer progresses, clinicians prescribe ADT to help improve patient life expectancy4. It 
functions to block androgen and androgen-cell receptors, including those associated with 
testosterone61. The most common mechanism by which ADT functions is through GnRH 
agonists, which have been shown to have similar effectiveness to surgical castration; however, 
some patients experience testosterone surges, which may have negative consequences in the 
development of prostate cancer62–64. For individuals with advanced PCa, the disease will 
eventually progress despite the use of GnRH agonists, as prostate tumors begin to mutate and 
overexpress androgens and androgen receptors65. This categorizes individuals as having castrate-
resistant prostate cancer, and ultimately lowers life expectancy and QoL66. Clinicians may detect 
this resistance to GnRH agonists through increases in prostate specific antigen (PSA): a 
biomarker that clinicians utilize as a potential indicator for the development of prostate cancer 
tumors59,67,68. The literature suggests that ADT is an effective remedy for patients with mPCa. 
Multiple studies have indicated ADT’s effectiveness in minimizing PSA levels at a rapid 
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rate,69,70 while also being a cost-effective solution71. However, the benefits of ADT do not come 
without consequences. 
 A large body of evidence suggests that those diagnosed with PCa on ADT have low QoL 
scores and suffer from functional deficits18,72. Although life expectancy can be increased, 
patients may find difficulty in having meaningful years. Studies have indicated that patients on 
ADT report worse health-related QoL measures as opposed to age-matched healthy controls and 
localized PCa subjects,73 due to the harsh side effects 
associated with testosterone suppression62. The 
effects progress when subjects are exposed to “super-
castration” drugs, such as abiraterone or 
enzalutamide. These drugs are commonly prescribed 
in conjunction with GnRH agonists and amplify 
negative side effects that subjects face. In fact, one 
study specifically found a significant loss in lean 
muscle mass after subjects started abiraterone 
therapy,10 indicating even worse outcomes for PCa 
patients. Clearly, solutions are needed to help 
mitigate losses in lean mass associated with ADT.  
 
Figure 1. Process of diagnosis of metastatic castration-resistant prostate cancer (mCRPC). In 
some cases, prostatectomy is not required as clinicians are aware that the cancer has spread to 
bone structures (metastatic).  
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Exercise in Cancer Patients 
 
 A large body of scientific literature supports the idea that exercise has many benefits for 
cancer patients, including improved balance, lower risk of heart disease, lower risk of 
osteoporosis, lower risk of disease reoccurrence, and improved QoL37,39,42,74–80. Studies even 
suggest that exercise can help in the prevention of cancer as well, as lifestyle factors play a 
pivotal role in the development of the disease81,82. In fact, a recent analysis conducted by Moore 
et. al (2016) indicated that exercise is associated with a lower risk of contracting at least thirteen 
different cancers83. Although these results were more generalizable to individuals with higher 
BMIs, it can be implied that greater levels of muscle mass, strength, and an enhanced immune 
system may be beneficial in the prevention of cancer84. While healthy lifestyle factors may help 
prevent cancers, they can also help maintain strength and physical fitness during cancer 
treatments. A recent systematic review provided evidence that exercise can provide cancer 
patients with both CV and muscular fitness benefits, along with improvements to QoL85. The 
same review indicated that these exercises have been shown to be safe, with a low probability for 
adverse events. Clearly, exercise is beneficial for this population, with minimal risk for injury; 
however, conflicts exist that may make adherence to physical activity problematic.  
 Physical activity guidelines for cancer survivors set by the American College of Sports 
Medicine (ACSM) are in some ways ambiguous. For example, some of the RT recommendations 
state to “start with supervised program and progress slowly,” but do not provide suggestions for 
exercise frequency or intensity. Also, many may have difficulties accessing a facility with staff 
who are qualified to work with at-risk popualtions86. Having ambiguous guidelines for this 
population may make adhering to a particular program difficult, and ultimately leads to less 
effective remedies for treating abnormalities that may accompany cancer survivors. Physical 
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activity barriers exist that limit cancer survivors from being able to exercise on a consistent 
basis87–89. Ultimately, these individuals have less accessibility to exercise, have less knowledge 
of various exercises to partake in, and have more limitations relative to other populations. 
Unfortunately, this is exacerbated in mCRPC patients, as they face a unique set of challenges due 
to the side effects of ADT. 
Exercise in PCa 
 
 The negative side effects associated with ADT leave PCa patients with losses in lean 
mass, resulting in decreases to physical function and overall QoL43. Coupled with the adverse 
effects of sarcopenia, men of this population become extremely sedentary90, resulting in an 
increased likelihood of contracting heart disease or diabetes mellitus16,53,91. Exercise has 
previously been researched as an advantageous tool for men of this population, as it may help to 
counteract harsh negative side effects (figure 2) exemplifies this mechanism37,39,42. Although 
multiple exercise regiments have been shown to be beneficial for PCa patients on ADT37,39,43, no 
detailed exercise guidelines exist for this population. Perhaps physiological data from exercise 
interventions can give insight to policy makers on creating exercise guidelines for this 
population, ultimately helping to increase longevity and QoL.  
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Figure 2. Mechanistic figure explaining exercise’s role in mitigating negative ADT side effects. 
 A recent meta-analysis has suggested that though RT is beneficial for men with PCa on 
ADT, further research should be done to investigate particular protocols that may yield the best 
results while optimizing patient safety92. Multiple studies have investigated specific exercise 
programs for this population, and have illustrated that it can be beneficial to fighting ADT side 
effects37–39. In particular, Hanson et. al (2013)39 found that a 12-week, supervised RT program 
for PCa patients receiving ADT significantly increased total body muscle mass by 2.7%, thigh 
muscle volume by 6.4%, power by 17%, and strength by 28%, suggesting that hypertrophy could 
occur even in the absence of testosterone. In addition to these physiological benefits, the same 
study found significant increases in patient physical function (20%), QoL (7%), and fatigue 
perception (38%). Another study by Galvao et. al (2018) 37 utilized a three-month, supervised 
program containing cardiovascular exercise, RT, and flexibility exercises. Results indicated that 
relative to sedentary subjects with the same disease, men on ADT who exercised experienced 
greater self-reported physical functioning and lower body muscle strength. The same study also 
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indicated that there were no exercise-related adverse events or skeletal fractures due to exercise, 
suggesting that the intervention was not only successful, but also safe. Undoubtedly, there are 
many benefits for PCa patients on ADT to reap from exercise; however, these programs need to 
be practical in order to increase adherence.   
One suggestion to increasing exercise practicality for men on ADT is home-based 
exercise. Home-based exercise would allow individuals to exercise in a more comfortable 
environment, overcoming physical activity barriers that may persist due to socioeconomic status, 
lack of fitness facilities, or low physical functioning48,89.  In addition, studies have reported that 
PCa patients may feel a level of embarrassment exercising at a facility and would also require 
staff members who are knowledgeable in working with at-risk populations86. Some studies 
suggest that home-based exercise can elicit positive outcomes to patient physiology and QoL93, 
but the literature is scarce regarding PCa populations. Some studies suggest that home-based 
exercise is feasible for PCa subjects. Kim et. al (2018)94 found an 80.4% 6-month exercise 
retention rate, and a 84.7% mean adherence rate for weight-bearing exercises. Beydoun et. al 
(2014)15 found that men on ADT who exercised saw significant improvements to 
cardiorespiratory and strength fitness variables, with 97% of subjects planning to continue 
exercise after program completion; however, the researchers did not distinguish differences 
between home-based and supervised exercise protocols.  
Previous literature has shown that home-based exercise can be feasible for prostate 
cancer populations, yet more research is needed to support this claim specifically for mCRPC. 
Men with PCa on ADT clearly suffer from lower QoL, and home-based exercise may be a way 
to provide an effective yet convenient solution. By assessing muscle cross-sectional area and 
volume, researchers will be able to assess important physiological variables that have been 
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previously associated with physical function and QoL. Health-care practitioners will be able to 
utilize this information by assessing these values in clinic and will hopefully obtain a greater 
understanding of patient well-being. 
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CHAPTER 3: METHODOLOGY 
 
Design and Procedures:  
 
Baseline and post-intervention testing occurred immediately prior to and after the 12-
week home-based exercise intervention, respectively. Weekly phone calls were made throughout 
the duration of the intervention to assess subject adherence to the protocol and to address 
problems and questions subjects may have had about the intervention. Patient Reported 
Outcomes (PROs) were given to subjects prior to both baseline and post-intervention testing. 
Notes regarding exercise adherence and general well-being were recorded and reported to the 
primary investigator in order to address conflicts. Any questions regarding the exercise program 
were also addressed via weekly phone calls (Figure 3).  
Subjects:  
 
Inclusion criteria for this study included men with metastatic, castration resistant prostate 
cancer (mCRPC) on androgen deprivation therapy (ADT) who had testosterone levels less than 
50ng/dL at the time of screening and had physician clearance to participate in moderate-to-
vigorous exercise. Exclusion criteria included having greater than 90 minutes of exercise per 
week within six months of screening, current chemotherapy, and diagnosis of cardiorespiratory 
diseases limiting subjects from participating in exercise.  After IRB-approval (#16-2427) was 
obtained, medical oncologists referred subjects to the study and referred individuals participated 
in an initial screening process. After an initial screening to confirm eligibility, a comprehensive 
medical history questionnaire was completed via telephone. The primary investigator reviewed 
the individual’s completed medical history to confirm the subject was eligible and healthy 
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enough. After explaining testing procedures, all subjects provided IRB-approved written 
informed consent and HIPAA authorization forms prior to testing. An age- and BMI- matched 
control (CON) group was recruited as a sample of convenience.  
 
Figure 3. Study Design 
Patient Reported Outcomes: 
 
Three questionnaires were used to assess PROs; these included the FACIT-Fatigue scale, 
the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer 
Therapy-Prostate (FACT-P). The Functional Assessment of Chronic Illness Therapy (FACIT)-
Fatigue scale was used to assess patient fatigue, and is known to have high internal validity 
(Cronblach’s alpha = 0.96) and high test-retest reliability (ICC = 0.95) 95. Scores range from 0-4, 
with higher scores corresponding to greater fatigue. The HADS questionnaire analyzes subject 
depression, and has been utilized as a valid questionnaire in research.96 The score calculates 
ranges from 0-21, with higher scores translating to greater amounts of depression and anxiety. 
The FACT-P is a widely accepted questionnaire that assesses physical, emotional, and functional 
well-being, in addition to prostate-cancer related health issues. It also contains five functional 
scales, three symptom scales, and a QoL scale. 
 
 




Body Composition was obtained through dual-energy x-ray absorptiometry (DEXA) scan 
(Discovery, Hologic, Marlborough, MA, USA). Total mass, lean mass, lean mass percentage, 
body fat percentage, bone mineral density, and bone mineral content were recorded. Upper body 
lean mass was calculated by adding lean mass values from the arms, trunk, and head. Lower 
body lean mass was calculated by adding the lean mass values from the legs. Appendicular lean 
mass was calculated by adding lean mass values from the arms and legs. All scans were 
completed by the primary investigator.  
Muscle Ultrasound 
 
Muscle cross-sectional area and echo intensity were obtained using ultrasound equipment 
(General Electric, Boston, MA, USA). Ultrasound measurements were taken from the mid-point 
of the greater trochanter of the femur and the lateral condyle of the tibia. Afterwards, cross-
sectional analysis of the vastus lateralis muscle was obtained. Three-five images were taken, 
dependent upon the clarity of the image taken. Afterwards, cross-sectional area and uncorrected 
echo intensity was analyzed using ImageJ software (NIH, Bethesda, MD, USA). Echo intensity 
was corrected using techniques by Young et. al 2015. 97 Coefficient of Variations were 
calculated and reported between and within investigators in order to minimize error. The images 
were also blinded by the primary investigator before analysis by other members of the research 
team.  
Physical Function Tests 
Physical function tests were designed to capture the ability to perform activities of daily 
living (ADLs). A short physical performance battery (SPPB) score was calculated from the five 
chair stands, 2.44-meter usual walk, and three balance tests. These tests were used to address 
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physical function in similar populations, and allowed the research team to make comparisons 
accordingly98. Other  tests included the 6-meter rapid walk, 2.44-meter usual walk, 8-foot timed 
up and go, three ten-second balance tests (including the semi-tandem, tandem, and neutral 
stances), five timed chair stands, timed stair-climb of ten steps, and a 400-meter walk. These 
tests were chosen due to their utilization in previous literature, allowing researchers to compare 
results to studies involving a similar population 39. Subjects were familiarized with all physical 
function tests (excluding the 400 meter walk) by attempting one practice run, and thirty seconds 
of rest were given between each trial to minimize fatigue.  
Exercise Intervention:  
 
The 12-week home-based exercise intervention consisted of a subject-individualized 
aerobic component (walking) and an RT component using resistance bands (Hygenic 
corporation, Akron, Ohio, USA). Heart rate reserve (HRR) was calculated through 
cardiorespiratory testing done at baseline, and subjects were asked to walk at a specific HRR 
range week-by-week. The intervention was designed to progressively increase exercise 
frequency and volume, as advised by the Exercise Oncology Guidelines set by the American 
College of Sports Medicine99. The aerobic component intensity, duration, and frequency started 
as low as 40% of HRR for 15 minutes, one time per week (week 1) and ended as high as 65% of 
HRR for 30 minutes, 4 times per week (week 12). Retention rates were also calculated, with a 
target rate of 66%.  
Exercise adherence was confirmed through the use of a Garmin VivoSmart HR 
smartwatch (Garmin, Olathe, KS, USA). This device was chosen due to its long battery life, cost, 
and ability for researchers to obtain HR and movement data remotely. Completion of 
cardiovascular exercise were confirmed if subjects had an elevated, steady HR in conjunction 
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with an increase in movement. Subjects were given resistance bands of four varying resistances 
(red, yellow, green, and blue) in order to promote intensity progression. Subjects were 
familiarized with upper body and lower body strength exercises. A member of the research team 
would show the subject the exercise and would ask them to repeat the exercise. The research 
team member would ensure that the exercise was completed correctly. The number of exercise 
sessions, sets, and repetitions varied weekly and in a graded fashion in order to promote strength 
gains amongst subjects. Subjects were then asked to record the time and day that exercises were 
completed in order for researchers to assess adherence. Subjects were compliant to an exercise 
session if 75% of the prescribed volume or exercises. Adherence was calculated by taking the 




 Statistical analysis was completed using SPSS version 25 (SPSS, INC., Durham, NC, 
USA). An a priori value was set to ⍺=0.05 for tests of significance. All statistics were reported 
as mean (standard deviation). Changes in MQ, VL CSA, physical function and QoL with training 
were assessed using dependent samples t-tests. Participant characteristics (mCRPC vs. CON) 
were assessed using independent samples t-tests. A one-way between subjects ANOVA was 
performed to compare differences in muscle CSA between CON, mCRPC Pre and mCRPC Post. 
Pearson correlation coefficients were calculated between changes in CSA and changes in 
physical function tasks. Effect sizes were calculated using Cohen’s d (M2-M1)/SDpooled
100 with 
0.2, 0.5, and 0.8 representing small, medium and large effects, respectively. Sensitivity analyses 
were conducted for individuals who meet or exceeded an adherence threshold of at least 70% of 
completed sessions, to explore if as differences may not be seen for those who did not comply to 
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the exercise intervention.  One-sample t-tests relative to 75% were performed for individual RT 
exercises to determine if they were infeasible.
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CHAPTER 4: RESULTS 
Subject Recruitment 
 Sixty-two men with mCRPC on ADT were referred to this study. Of the sixty-two who 
were referred, 35.4% were eligible and decided to participate (n=22). (Figure 4).  
  
 
Figure 4. Consort diagram.  
 
Referred to study 
(n=62)
Did Not Participate 
(n=40)
- Unresponsive (n=14)
- Ineligible: Too active (n=12)
- Uninterested (n=11)
- Too unhealthy (n=2)
- Not mCRPC (n=1)




Did not complete 
intervention (n=7)
- Did not want to post test (n=4)
- Poor prognosis (n=1)
- Drop out due to knee pain (n=1)
- Drop out due to back pain (n=1)
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Descriptive Statistics  
 No significant differences were seen in descriptive variables between mCRPC and CON 
(Table 1). For the mCRPC group, all men were prescribed castrate-resistant ADT throughout the 
duration of the study. Information on other medications prescribed due to cancer diagnosis is 
also provided (Table 2). 
Table 1. Participant characteristics between 
Metastatic, castration-resistant prostate cancer 
participants (mCRPC) (n=15) and Control (CON) 
(n=17)  
 
mCRPC   CON p-value 
Age (y)  72 (7) 69 (3) 0.650 
Height (cm) 174 (8) 177 (7) 0.280 
Mass (kg) 97 (21) 102 (9) 0.160 
BMI (kg/m2) 32 (7) 33 (2) 0.340 
Mean (SD), BMI=body mass index. mCRPC= 
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Table 2. Cancer treatments for metastatic, castration-resistant prostate 
cancer (mCRPC) participants (n=15) 
Number on ADT 15 
Duration of ADT (months) 36 (33) 
Duration of CR ADT (months) 7 (5) 
Type of ADT 
 
     LHRHa, n(%) 1 (8) 
     Antiandrogen, n (%) 4 (28) 
     LHRHa + antiandrogen, n (%) 10 (65) 
Previous Prostatectomy, n (%) 7 (46) 
Previous Radiotherapy, n (%) 10 (65) 
Previous Chemotherapy, n (%) 4 (26) 
Time since chemotherapy (months) 13 (5) 
Mean (SD), ADT = Androgen Deprivation Therapy, CR = Castrate-
Resistant, LHRHa = Luteinizing-Hormone-Releasing-Hormone Agonist 
 
Retention and Adherence 
 
Retention rates for the study was 68%, which met the target rate of 66%. The average 
total exercise adherence across the trial was 72.9% (23.3), with walking and resistance 
adherences at 80.1% (17.0) and 65.5% (29.5), respectively, which also met the targeted 
adherence of 75% (Figure 5). Adherence values for the exercise intervention were somewhat 
variable on a week to week basis (Figure 6), with the lowest average adherence for walking 
occurring at week 5 (68%) and for resistance training at week 10 raining (50%).   
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Figure 5. Summary of weekly adherence levels 
(individual exercises) for men who completed the 
intervention (n=14). Adherence is calculated for each 
week by dividing the number of sessions completed 
by the number of sessions prescribed by the research 




Figure 6. Summary of weekly adherence levels (bolded line walking, dotted line RT) for men 
who completed the intervention (n=14). Adherence is calculated for each week by dividing the 
number of sessions completed by the number of sessions prescribed by the research team.  Data 
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The exercises that were significantly different relative to the target value (75%) were all 
of the floor abdominal exercises (all p<0.01, Figure 7) and push-ups (p=0.045).  
Figure 7. Exercise Adherence 
during the 12-week Home-based 
exercise intervention. Study 
adherence targets were 75% (red 










Vastus Lateralis CSA and MQ and Physical Function Tasks 
 
Small to moderate increases in VL CSA were observed following the exercise 
intervention, with a 12.6% increase between baseline and post-intervention testing (p=0.012, d 
=0.32; Figure 8). Compared with controls (Average CSA 36.55 (6.02)), baseline VL CSA was 
136% less (p<0.01, d = 5.75) and post-intervention was 127% less (p<0.01, d = 5.28). No 
differences occurred in VL MQ between pre and post-intervention testing (p=0.37, d = 0.22, 
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Figure 8. Vastus lateralis cross-sectional area (CSA) data for men who completed the 
12-week home-based exercise intervention (n=14) compared to CON.  
mCRPC = Metastatic, castration-resistant prostate  
cancer, CON = Control 
*p<0.05 compared to mCRPC Pre  
# p<0.01compared to mCRPC Post 
Figure 9. Vastus Lateralis Muscle 
Quality (MQ) data for men who 
completed the 12-week home-based 
exercise intervention (n=14).  
mCRPC = Metastatic, castration-
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There were no changes in physical function in men with mCRPC who completed the 
intervention (Table 3). 
Table 3. Summary of Results from Vastus Lateralis Cross-sectional area, Vastus Lateralis 
muscle quality, and Physical Function testing for men who completed the exercise intervention 
(n=14) 
 
Pre Post p-value Cohen’s d 
SPPB 10.5 (2.2) 11.0 (1.8) 0.130 0.28 
5 Chair stands (sec) 13.1 (5.0) 12.4 (5.8) 0.210 0.14 
6m Rapid Walk (sec) 4.5 (1.6) 4.6 (1.5) 0.380 0.08 
8ft TUG (sec) 10.5 (11.1) 10.9 (11.3) 0.590 0.03 
Stair Climb (sec) 6.5 (2.8) 6.3 (3.1) 0.250 0.08 
400m walk (sec) 307.8 (127.0) 292.6 (116.8) 0.110 0.12 
Mean (SD), VL = Vastus Lateralis, CSA = Cross-Sectional Area, MQ = Muscle Quality, SPPB 
= Short Physical Performance Battery, TUG = Timed-up and Go 
 
Due to changes in VL CSA after the exercise intervention, correlation coefficients were 
determined to explore if greater changes in CSA correlates with changes in physical function 
tests. Beneficial relationships were observed between CSA changes and SPPB, 5 Chair stands, 
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Table 4. Correlation Coefficient Table for changes in physical function tasks for men 
who completed the intervention. All Correlation Coefficients are compared to changes in 
Vastus Lateralis cross-sectional area for men who completed the exercise intervention 
(n=14) 
Task SPPB Chair 6m Walk TUG Stair Climb 400m walk 
Pearson’s R 0.36 -0.32 0.20 0.20 -0.17 -0.33 
p-value 0.19 0.24 0.47 0.47 0.54 0.22 
SPPB = Short Physical Performance Battery, Chair = 5 Chair Stands, Rapid = 6m Rapid 





Due to heterogeneity in adherence levels, sensitivity analysis was required to examine 
how program adherence could affect the variables of interest. Of the fifteen men who completed 
the exercise intervention, nine completed the intervention with the desired adherence levels of at 
least 70% of completed exercise sessions. Men who completed the intervention and met the 
adherence threshold (n=9) had a 28.6% increase in muscle CSA between baseline testing and 
post-intervention testing (p=0.008, d = 0.70; Table 6). MQ did not change following training 
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Table 5. Sensitivity analysis for Vastus Lateralis cross-sectional area, Vastus Lateralis muscle 
quality, and physical function testing for men who had met the exercise adherence threshold of 
at least 70% for total adherence (n=9).  
 Pre Post p-value Cohen’s 
d 
VL CSA (cm2) 9.2 (3.1) 11.7 (4.0) 0.010 0.70 
VL MQ 109.1 (16.7) 113.4 (15.6) 0.500 0.27 
SPPB 10.6 (1.9) 11.2 (1.4) 0.250 0.34 
Chair Stand (sec) 10.1 (2.4) 9.8 (4.1) 0.490 0.11 
6m Rapid Walk 
(sec) 
4.6 (1.5) 4.6 (1.1) 0.960 0.01 
8ft TUG (sec) 10.9 (11.9) 11.6 (14.6) 0.490 0.05 
Stair Climb (sec) 6.5 (3.1) 6.5 (3.5) 0.950 0.01 
400m Walk (sec) 335.4 (114.2) 321.8 (103.1) 0.370 0.12 
Mean (SD), VL = Vastus Lateralis, CSA = Cross-Sectional Area, MQ = Muscle Quality, TUG 
= Timed-Up and Go 
 
Correlation coefficients were calculated in order to understand the relationship between 
changes in CSA and changes in various physical function tests for men who completed the 
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Table 6. Correlation between changes in Vastus Lateralis cross-sectional area and 
physical function tasks for individuals who met our adherence threshold (n=9) 
Task SPPB Chair 6m Walk TUG Stair Climb 400m walk 
Pearson’s R 0.30 -0.35 -0.25 0.28 -0.06 -0.14 
p-value 0.43  0.36  0.52 0.46  0.88  0.72 
SPPB = Short Physical Performance Battery, Chair = 5 Chair Stands, Rapid = 6m 




   
 32
 
CHAPTER 5: DISCUSSION 
ADT is commonly prescribed during PCa to increase survival, but is accompanied by 
muscle atrophy and decreases in physical function and QoL16,18–20,101. Exercise training improves 
many of these outcomes in less progressive forms of PCa37,39–41. However, it is unknown if 
exercise improves body composition and physical function in advanced disease (e.g. mCRPC), 
particularly when looking at more sensitive and localized measures. Following a 12-week, home-
based exercise intervention, VL MQ was unchanged while CSA increased by 12.6% following 
training. Greater adherence to training lead to greater improvements in CSA. Physical function 
was unchanged with training and was not associated with improvements in CSA. Preliminary 
data would suggest that exercise can induce increases to muscle size in this population, but that 
hypertrophy does not correspond with changes to physical function.   
Limitations and Strengths 
 
The current study had several limitations. The first was the lack of a control group. 
However, this was a feasibility trial and all participants were allocated to exercise because it was 
unknown if mCRPC would participate in home-based exercise to maximize the number of 
individuals that would potentially complete the intervention. Secondly, all testing was completed 
in the same day, which can increase subject fatigue during testing. However, subjects potentially 
had to travel great distances, and rest periods were incorporated. Thirdly, length and type of 
ADT affects the severity of side effects10, but was not controlled for due to a limited sample size. 
Lastly, adherence values for the resistance training portion of the exercise intervention were self-
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report and highly variable, but participants were contacted weekly, which improves home-based 
exercise adherence102,103.  
This study contained several strengths. This is the first trial to quantify differences in 
muscle CSA and MQ in mCRPC following training and compared to non-cancer controls and all 
scans were blinded to reduce analysis bias. The home-based approach likely helped to mitigate 
physical activity barriers. Although there was no dedicated familiarization session (Hanson 
2016), subjects practiced all tasks prior to testing of functional tasks, which may have helped 
reduce error that may have occurred due to learning effects.  
Key Findings  
 
 To our knowledge, this is the first study to examine the effects of exercise training on 
regional body composition and physical function in mCRPC undergoing ADT. This sample 
demonstrated localized muscle hypertrophy with no changes to MQ following exercise (Figure 8 
and 9). Of note, VL CSA was ~4x smaller than an age- and BMI-matched control group, but 
training appeared reverse ADT side effect (Figure 8, d=0.32), with greater adherence leading to 
additional benefits (Table 6, d= 0.7). Although improvements in regional body composition were 
observed, total body composition was only maintained, and suggests the importance of 
ultrasound measurements to accurate depict changes in body composition for this population. 
However, given that this occurred during a period where a loss of lean mass may be likely10,13 
maintenance of lean mass may still be clinically important.  
Comparisons to the Literature 
 
The differences between mCRPC and CON from this study illustrate the severity of 
atrophy that accompanies mCRPC. However, training appeared  to partially counteract ADT-
related VL muscle loss (Figure 8) and is consistent with previous work done in less progressive 
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stages of disease9,15,25,37,39,40,104. While Hanson et. al (2013)39 showed regional hypertrophy (thigh 
muscle volume) in localized PCa survivors on ADT, the current trial demonstrated similar 
outcomes in more advanced disease with a less vigorous and more convenient model of training. 
Additionally, 3 months of supervised exercise for PCa subjects with bone metastases undergoing 
ADT increased physical function37. Subjects from Galvão (2018) had only been prescribed ADT 
for a relatively short period of time (median 2 months, IQR (1.0-6.3)), whereas participants from 
the current study were 1) clinically diagnosed with more progressive disease (mCRPC) and 2) 
chronically prescribed primary ADT (average 36 months, standard deviation (33); Table 2). 
Time on ADT significantly impacts physical function 10,105 and would suggest that the sample 
used for the current study was arguably more compromised. Nevertheless, physical function 
appears to have been maintained, which is potentially promising in mCRPC, although needs to 
be confirmed using non-exercising controls.  
Exercise adherence likely plays a critical role in mediating the beneficial adaptations that 
occurred from this study. Overall, there was a 12.6% increase in VL CSA of (n=14, p=0.012, 
Cohen’s d= 0.32; Figure 8). However, when only individuals with an adherence threshold of 
70% or greater were analyzed, relative muscle hypertrophy were more than twice as great 
(26.8%, n=9, p<0.01, Cohen’s d = 0.70; Table 6). The large difference of effect size between the 
two groups suggests that higher exercise frequency may be important in a home-based approach, 
perhaps due to training stimuli that are likely less intense relative to supervised exercise training. 
Additionally, 40% of the men who completed this intervention did not meet our adherence 
threshold, this is an area to be targeted in future investigations.  
One possible explanation for the lower adherence may be due to the difficulty of certain 
individual exercises, as there were RT exercises that yielded adherence thresholds of less than 
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50%, including all the floor-based core exercises and push-ups. Given the age and mobility 
limitations of our subjects, this low adherence is not surprising but illustrates a need for 
alternative core exercises in future interventions. On the contrary, all other exercises generated 
adherence rates of at least 60% and were not statistically different than the 75% adherence 
threshold established at the start of the study (Figure 7). In addition, increased exercise frequency 
(and volume) also may have influenced adherence rates, with the lowest adherence rates at week 
5 for walking (71%) and week 10 for RT (52%) (Figure 5).  For example, at week 5 the walking 
sessions increase from three to four times a week, perhaps indicating that they may have 
difficulty adjusting to the greater exercise frequency or that a potential volume threshold may 
exist. Future studies should look to implore motivational tactics (including appropriate 
theoretical behavioral models) to help account for weeks with increased exercise frequency or 




Results from this study suggest that exercise can potentially benefit this population. 
However, the impact is unclear without the use of a control group and demonstrates a need for 
randomized control trials to determine the efficacy of exercising training during mCRPC. 
Unsurprisingly, additional benefits appear to occur with greater adherence to the program (Table 
6; d=0.70), and emphasizes the importance of increased exercise frequency. Future work should 
consider methodology that would incorporates a control group, as well as utilizing strategies to 
help increase adherence. Hybrid exercise interventions that use telemedicine are a viable option, 
in which exercise professionals would virtually supervise home-based exercise sessions. 
Participants can potentially exercise in the comfort of their home, while simultaneously 
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exercising with a trained and qualified individual in the field. Ultimately, this would help to 
conquer many physical activity barriers and would hopefully provide greater adherence levels for 
home-based exercise in this population.  
Conclusions 
 Exercise has previously been shown to counteract the consequences of ADT, but men 
with more progressive PCa, specifically mCRPC, are understudied. The purpose of this study 
was to examine changes to muscle CSA and MQ in men with mCRPC undergoing ADT, how 
changes correlated with physical function, and how they compare with age- and BMI-matched 
controls. Results indicated that this population suffers from extremely low regional muscle mass 
compared to CON, but that home-based exercise training induces hypertrophy that helps to 
alleviate the deficit. However, regional hypertrophy was not associated with changes in physical 
function. Although an apparent exercise threshold was indicated, men who exceeded this 
threshold experienced effects more than 2x greater of those who did not. The home-based 
exercise intervention should be improved upon for future studies, and researchers should 
consider the use of hybrid exercise interventions that utilize technology. 
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APPENDIX A: WEEKLY FOLLOW-UP FORM 
 
Weekly Follow-Up Form 
 
Participant: (subject #) 
 
Date, Week of Intervention: 
 
 






APPENDIX B: GARMIN SMARTWATCH INSTALLATION INSTRUCTIONS 
 
Garmin Data Extraction Instructions: 
1. Log in to Garmin Connect account. 
2. Go to “Daily Summary.” 
3. Record times in which session criteria are met. 
 
Session Criteria: 
1. Elevated heart rate combined with increase in step count 
2. Elevations in heart rate and step count must be sustained for at least half of the duration 




APPENDIX C: GARMIN SMARTWATCH EXTRACTION INSTRUCTIONS 
Exercise log extraction instructions: 
1. Call the subject beforehand to ensure that they bring the appropriate test materials before 
post-intervention testing 
2. Once the log has been obtained, confirm that the subject has filled the log out 
appropriately. Kindly ask the subject about any misconceptions in the log.  
3. Once the research team member has confirmed that the log has been appropriately filled 
out, count the number of RT and walking sessions completed on a weekly basis. Only 
count the day as a session if at least 75% of the prescribed exercise has been completed 
4. If a particular RT exercise was NOT completed, specify in the data. 
5. If the subject completed some RT exercises but not enough to satisfy an entire session, 





APPENDIX D: GARMIN SMARTWATCH SETUP INSTRUCTIONS 
 
Garmin Account Setup Procedure: 
1) Create a gmail account.  
- Go to https://accounts.google.com/SignUp?hl=en and fill in the information 
- We have been using uncexss0xx@gmail.com where “xx” is the subject number. 
- It is not important to have the participant’s information correct for the gmail account, 
as only we will access it and it will not affect the data in any way. 
2) Create a Garmin Connect account that is tied to that gmail account. 
- Go to https://connect.garmin.com/en-US/signin and click “create one” 
- Create an account using the gmail address that you just created. Agree to the terms 
and conditions and click “create account.” 
- Select “activity tracking” and “fitness” to display on the dashboard. 
- Go to “account settings” and update their “user settings” to give them an accurate 
height and weight whenever these are known 
3) Sync the watch to the new Garmin account. 
- Download Garmin Express: https://www.garmin.com/en-US/software/express  
- Open Garmin Express once it is finished downloading 
- Open the watch from the box. Turn it on and set the appropriate time and date; do not 
connect with Bluetooth. Connect the watch to the charging cable and plug USB end 
of the cable into your computer. 
 
 41
- On your computer in the Garmin Express app, click “add device.” Allow the 
computer to search for and find the watch, and click “add device.” 
- Register the watch using the gmail address used to make the Garmin Connect 
account. Follow prompts on screen. The watch will now be connected to the Garmin 
Connect Account that you created. 
- Go to Garmin Connect https://connect.garmin.com/en-US/signin and sign in using the 
account information you used earlier. In the upper right hand corner, click the watch 
icon. It should now say “vivosmart HR” (or whatever you nicknamed the watch if 
you did so). This website is where their information will be available whenever they 
sync the watch to their account. 
- Update the watch if necessary. 
4) Ensure participant is syncing to correct account on baseline testing day 
- They can use either Garmin Connect their smartphone or Garmin Express on their 
computer. 
- If they use their phone, download the Garmin Connect app. Sign them in using the 
account information associated with the watch they are being given. Make sure 
Bluetooth is turned on. On the watch, click the menu button on the side of the watch, 
and scroll to the Bluetooth icon. Press “pair smartphone.” On their phone, click “add 
device.” Complete the sync process, and data will periodically sync as long as the 
Bluetooth connection is maintained. 
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- If they elect to use their computer, they will need to download Garmin Express on 
their computer and add the device in the same way as described above. The watch 
will already be registered to the appropriate account, so they will stop after clicking 
“add device.” The participant will need to periodically connect the charging cable 
into the computer and open the Garmin Express App. In the app, they can click on the 
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